Dosing and administration across all indications¹

Reduced dose in comparison to the initial maintenance dose of 200 mg every 2 weeks may be considered in patients with severe, active axSpA who are in sustained remission after at least 1 year of treatment.^1,2,a

Adapted from Cimzia SmPC and Landewé R, et al. Ann Rheum Dis. 2020

^a Patients received CIMZIA^® 200 mg every 2 weeks after a loading dose of CIMZIA^® 400 mg at weeks 0, 2 and 4. At week 48, patients in sustained remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 at weeks 32 or 36, and 48) were randomised to CIMZIA^® 200 mg every 2 weeks (full maintenance dose), CIMZIA^® 200 mg every 4 weeks (reduced maintenance dose) or placebo (withdrawal) for an additional 48 weeks.²

^b Treatment should be guided according to a predefined treatment target.²

After the starting dose, the recommended maintenance dose of Cimzia^® for adult patients with axial spondyloarthritis is 200 mg Q2W or 400 mg Q4W. After at least 1 year of treatment with Cimzia^®, in patients with sustained remission, a reduced maintenance dose of 200 mg Q4W may be considered.